All In Biotech

Drug Trial Radar · NCT07578363

An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults

A Multicenter, Randomized, Vehicle-Controlled Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness in Adult Subjects

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Sep 27, 2026

Primary completion

Nov 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
May 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.

Conditions

  • Ocular Hyperemia

Interventions

  • Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative FreeDrug

    Investigational ophthalmic solution applied topically to the eye in a unit dose preservative free formulation

  • VehicleDrug

    Inactive ingredients of FID 123472 applied topically to the eye as an ophthalmic solution in a unit dose preservative free formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in investigator-assessed ocular redness at 15 minutes post-instillation on Day 1Time frame: Baseline (Day 1 pretreatment); 15 minutes post-instillation (Day 1)
  2. Change from baseline in investigator-assessed ocular redness at 600 minutes post-instillation on Day 1Time frame: Baseline (Day 1 pretreatment); 600 minutes post-instillation (Day 1)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Wyse Eyecare

    Northbrook, Illinois · Not yet recruiting

  • Oculus Research, Inc.

    Garner, North Carolina · Recruiting

  • CORE, Inc.

    Shelby, North Carolina · Not yet recruiting

  • Total Eye Care PA

    Memphis, Tennessee · Recruiting

  • Piedmont Eye Center

    Lynchburg, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.